Meridian's Group B Streptococcus Test Approved for Sale in Australia | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Meridian Bioscience's wholly owned subsidiary Bioline announced today that its illumigene Group B Streptococcus test has received regulatory approval for commercialization in Australia.

Clearance from the Therapeutic Goods Administration follows similar action in the US by the Food and Drug Administration.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.